BREAST CANCER RESISTANCE PROTEIN - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 346

45. Chen, ZS, Lee, K, Walther, S, Raftogianis, RB, Kuwano, M, Zeng, H, and Kruh, GD. 2002.
Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4):
MRP4 is a component of the methotrexate efflux system. Cancer Res 62:3144-3150.
46. Muller, M, Bakos, E, Welker, E, Varadi, A, Germann, UA, Gottesman, MM, Morse, BS,
Roninson, IB, and Sarkadi, B. 1996. Altered drug-stimulated ATPase activity in mutants
of the human multidrug resistance protein. J Biol Chem 271:1877-1883.
47. Ozvegy, C, Varadi, A, and Sarkadi, B. 2002. Characterization of drug transport, ATP hy-
drolysis and nucleotide trapping by the human ABCG2 multidrug transporter: modulation
of substrate specificity by a point mutation. J Biol Chem 277:47980-47990.
48. Ee, PL, Kamalakaran, S, Tonetti, D, He, X, Ross, DD, and Beck, WT. 2004. Identification
of a novel estrogen response element in the breast cancer resistance protein (ABCG2)
gene. Cancer Res 64:1247-1251.
49. Imai, Y, Ishikawa, E, Asada, S, and Sugimoto, Y. 2005. Estrogen-mediated post transcrip-
tional down-regulation of breast cancer resistance protein/ABCG2. Cancer Res 65:596-
604.
50. Wang, H, Zhou, L, Gupta, A, Vethanayagam, RR, Zhang, Y, Unadkat, JD, and Mao, Q.
2005. Regulation of BCRP/ABCG2 expression by progesterone and 17 { beta } -estradiol
in human placental BeWo cells. Am J Physiol Endocrinol Metab 290:E798-807.
51. Yasuda, S, Itagaki, S, Hirano, T, and Iseki, K. 2005. Expression level of ABCG2 in the
placenta decreases from the mid stage to the end of gestation. Biosci Biotechnol Biochem
69:1871-1876.
52. Tanaka, Y, Slitt, AL, Leazer, TM, Maher, JM, and Klaassen, CD. 2005. Tissue distribution
and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and
mice. Biochem Biophys Res Commun 326:181-187.
53. Merino, G, Jonker, JW, Wagenaar, E, van Herwaarden, AE, and Schinkel, AH. 2005. The
breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary
excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol 67:1758-
1764.
54. Krishnamurthy, P, Ross, DD, Nakanishi, T, Bailey-Dell, K, Zhou, S, Mercer, KE, Sarkadi,
B, Sorrentino, BP, and Schuetz, JD. 2004. The stem cell marker Bcrp/ABCG2 en-
hances hypoxic cell survival through interactions with heme. J Biol Chem 279:24218-
24225.
55. Mogi, M, Yang, J, Lambert, JF, Colvin, GA, Shiojima, I, Skurk, C, Summer, R, Fine,
A, Quesenberry, PJ, and Walsh, K. 2003. Akt signaling regulates side population cell
phenotype via Bcrp1 translocation. J Biol Chem 278:39068-39075.
56. Takada, T, Suzuki, H, Gotoh, Y, and Sugiyama, Y. 2005. Regulation of the cell surface
expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized
cells. Drug Metab Dispos 33:905-909.
57. Mickley, LA, Spengler, BA, Knutsen, TA, Biedler, JL and Fojo, T. 1997. Gene rearrange-
ment: a novel mechanism for MDR-1 gene activation. J Clin Invest 99:1947-1957.
58. Hazlehurst, LA, Foley, NE, Gleason-Guzman, MC, Hacker, MP, Cress, AE, Greenberger,
LW, De Jong, MC, and Dalton, WS. 1999. Multiple mechanisms confer drug resistance
to mitoxantrone in the human 8226 myeloma cell line. Cancer Res 59:1021-1028.
59. Allen, JD, Brinkhuis, RF, Wijnholds, J, and Schinkel, AH. 1999. The mouse
Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for re-
sistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59:4237-4241.